EUVIMEDEUVIMED entdecken
Open Access

Stability Study of Compounded Ethanol-Free Buprenorphine Oral Syringes for the Treatment of Neonatal Opioid Withdrawal Syndrome

Viren Soni, Samarth A Shah, Walter K Kraft, Gagan Kaushal

The Journal of Pediatric Pharmacology and Therapeutics · 17.03.2026

DOI: 10.5863/jppt-25-00058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pediatric Pharmacology and Therapeutics, erschienen am 17.03.2026. Verfasst von Viren Soni und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences (VS, SAS, GK), Thomas Jefferson University, Philadelphia, PA. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Buprenorphine (BUP) is advantageous in the management of neonatal opioid withdrawal syndrome (NOWS). A widely used BUP formulation for the treatment of NOWS contains 30% ethanol. This study aimed to investigate the stability of BUP in compounded ethanol-free oral syringes. METHODS A 75-mcg/mL BUP solution was prepared by diluting the commercial injectable solution with water for irrigation, transferred into amber oral syringes, and stored at either room temperature (n = 3) and refrigerated (n = 3) conditions. Microbial testing of the compounded oral syringes was performed to determine microbial growth for 24 and 48 hours at 37°C. The stability of BUP was assessed in the compounded syringes was conducted by pH and liquid chromatography-mass spectrometry (LC-MS) analysis after compounding and at 7, 30, and 60 days of storage. RESULTS The concentration of BUP at all time points was between 90% and 110% of the baseline on day 0. Concentration increased slightly in the oral syringes after day 30, likely due to moisture loss, as there were no degradation peaks observed in chromatograms. There was no microbial growth or visual change observed for the compounded ethanol-free BUP oral syringes. The pH of the oral syringes was consistent through 60 days for both room-temperature and refrigerated samples. CONCLUSION Buprenorphine in an ethanol-free formulation is stable and can be easily compounded in pediatric pharmacies. This formulation is appealing for the treatment of NOWS.

Schlagwörter

Stichwörter der Autor:innen

buprenorphinedrug compoundingdrug stabilityneonatal opioid withdrawal syndromeoral syringes.

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences (VS, SAS, GK), Thomas Jefferson University, Philadelphia, PA.
  • Department of Pharmac ology, Physiology & Cancer Biology (VS, WKK), Thomas Jefferson University, Philadelphia, PA.

Zitieren

APA

Soni, V., Shah, S. A., Kraft, W. K., & Kaushal, G. (2026). Stability Study of Compounded Ethanol-Free Buprenorphine Oral Syringes for the Treatment of Neonatal Opioid Withdrawal Syndrome. The Journal of Pediatric Pharmacology and Therapeutics. https://doi.org/10.5863/jppt-25-00058

Vancouver

Soni V, Shah SA, Kraft WK, Kaushal G. Stability Study of Compounded Ethanol-Free Buprenorphine Oral Syringes for the Treatment of Neonatal Opioid Withdrawal Syndrome. The Journal of Pediatric Pharmacology and Therapeutics. 2026. doi:10.5863/jppt-25-00058

BibTeX
@article{Soni2026,
  author = {Soni, Viren and Shah, Samarth A and Kraft, Walter K and Kaushal, Gagan},
  title = {Stability Study of Compounded Ethanol-Free Buprenorphine Oral Syringes for the Treatment of Neonatal Opioid Withdrawal Syndrome},
  journal = {The Journal of Pediatric Pharmacology and Therapeutics},
  year = {2026},
  doi = {10.5863/jppt-25-00058}
}
Kostenlos starten →